HETEROCYCLES, Vol. 80, No. 1, 2010
161
8. G. Chen, N. Tokunaga, and T. Hayashi, Org. Lett., 2005, 7, 2285.
9. C. Defieber, J.-F. Paquin, S. Serna, and E. M. Carreira, Org. Lett., 2004, 6, 3873.
10. General procedure for the reactions of coumarin analogues: A 20 mL Schlenk flask was charged
with (R)-MeO-F12-BIPHEP (12.4 mg, 15.5 μmol), μ-dichlorotetraethylene dirhodium(I) (3.0 mg, 7.7
μmol) and 0.5 mL of deoxygenated toluene under argon atmosphere. The mixture was stirred at
room temperature for 5 min for complexation. To the mixture was added 2.5 mL of deoxygenated
toluene, phenylboronic acid (1.89 g, 15.5 mmol), 2.0 mL of deoxygenated sat. NaHCO3 aq, and
coumarin (3a, 227 mg, 1.55 mmol). After being stirred at 30 °C for 1 h, to the solution was added
saturated aqueous NaHCO3 solution. The resulting mixture was extracted with EtOAc (three times).
The organic layer was dried over MgSO4, filtrated with suction, and then concentrated under reduced
pressure. The residue was purified by silica gel column chromatography (Hexane / EtOAc = 3/1) to
give (R)-4-phenylchroman-2-one (4a) as a white solid (327 mg, 94% yield, >99% ee).
m.p. 114 – 115 °C; 1H NMR (300 MHz, CDCl3): δ 3.01 (dd, J = 14.7, 7.8 Hz, 1H), 3.08 (dd, J = 14.7,
7.8 Hz, 1H), 4.32 – 4.36 (m, 1H), 6.96 – 6.99 (m, 1H), 7.08 (dt, J = 7.2, 1.2 Hz, 1H), 7.12 – 7.17 (m,
3H), 7.25 – 7.38 (m, 4H); 13C NMR (75 MHz, CDCl3): δ 36.9, 40.6, 117.1, 124.6, 125.7, 127.5,
127.6, 128.3, 128.8, 129.1, 140.2, 151.7, 167.6; IR (KBr): 1767, 1497, 1454, 1418, 1335, 1277, 1202,
30.2
1188, 1134, 966, 895, 816, 760, and 708 cm-1; [α]D
–41.1° (c 1.0, CHCl3); HPLC (Daicel
Chiralcel OD-H, Hexane/i-PrOH = 95/5, flow rate = 1.0 mL/min) tR of (S)-4a: 13.8 min (0%); tR of
(R)-4a: 15.2 min (>99%).
11. (R)-6-Methyl-4-phenylchroman-2-one (4b): m.p. 112 – 113 °C; 1H NMR (300 MHz, CDCl3): δ 2.25
(s, 3H), 2.98 (dd, J = 15.6, 6.3 Hz, 1H), 3.06 (dd, J = 15.6, 6.3 Hz, 1H), 4.27 – 4.31 (m, 1H), 6.78 (m,
1H), 7.02 (d, J = 8.4 Hz, 1H), 7.07 – 7.17 (m, 3H), 7.25 – 7.38 (m, 3H); 13C NMR (75 MHz, CDCl3):
δ 20.7, 37.1, 40.7, 116.8, 125.3, 127.5, 127.6, 128.6, 129.1, 129.3, 134.3, 140.5, 149.6, 167.8; IR
(KBr): 1760, 1610, 1587, 1487, 1450, 1339, 1337, 1221, 1205, 1136, 1111, 966, 908, 874, 767, 756,
and 700 cm-1; [α]D30.7 –3.6° (c 1.0, CHCl3); HPLC (Daicel Chiralcel OD-H, Hexane/i-PrOH = 90/10,
flow rate = 1.0 mL/min) tR of (S)-4b: 12.2 min (0%); tR of (R)-4b: 14.0 min (>99%).
1
12. 7-Methoxy-4-phenylchroman-2-one (4c): m.p. 133 – 134 °C; H NMR (300 MHz, CDCl3): δ 2.98
(dd, J = 15.9, 7.8 Hz, 1H), 3.07 (dd, J = 15.9, 7.8 Hz, 1H), 3.80 (s, 3H), 4.26 – 4.31 (m, 1H), 6.63
(dd, J = 8.4, 2.7 Hz, 1H), 6.69 (d, J = 2.7 Hz, 1H), 6.85 – 6.88 (m, 1H), 7.13 – 7.17 (m, 2H), 7.25 –
13
7.37 (m, 3H); C NMR (75 MHz, CDCl3): δ 37.3, 40.1, 55.5, 102.5, 110.7, 117.6, 127.5, 127.6,
128.9, 129.1, 140.7, 152.4, 160.0, 167.6; IR (KBr): 1755, 1629, 1585, 1508, 1456, 1325, 1267, 1221,
31.3
1134, 1109, 1030, 972, 880, 833, 752, and 700 cm-1; [α]D –43.0° (c 1.0, CHCl3); HPLC (Daicel
Chiralcel OD-H, Hexane/i-PrOH = 95/5, flow rate = 1.0 mL/min) tR of minor enantiomer of 4c: 17.3
min (0%); tR of major enantiomer of 4c: 21.5 min (>99%).